Cel
Current methods of screening for breast and colorectal cancer are limited in availability and associated with a high cost. For example, mammography equipment for breast cancer screening is particularly limited in Eastern Europe due to the expensive equipment and the required skills that a medical professional must possess. Cologaurd’s and colonoscopy’s for colorectal cancer screening are invasive and painful procedures associated with low patient compliance (50% and 37% respectively). Furthermore blood tests that have been developed to date for cancer screening have failed to demonstrate a high level of accuracy.
Todos Medical have developed a simple method for cancer screening known as TBIA (Total Biochemical Infrared Analysis). The CE-marked TBIA platform is unique being the first method using blood tests to show high sensitivity (>90%) and high specificity (>80%). It is a more cost effective and less invasive solution that is more accessible to end user and motivates increased compliance by patients. It is capable of producing results rapidly with the complete process “sample to result” taking less than 4 hours.
During phase 1, a feasibility study will be carried out, together with the planning of clinical trials in hospitals that will be performed during the innovation project, to gain the validation and bring the product to the commercialization.
Dziedzina nauki
- medical and health sciencesbasic medicineimmunology
- social scienceseconomics and businessbusiness and managementbusiness models
- medical and health sciencesclinical medicineoncologybreast cancer
- medical and health sciencesclinical medicineoncologycolorectal cancer
- engineering and technologymedical engineeringmedical laboratory technologylaboratory samples analysis
Program(-y)
Temat(-y)
Zaproszenie do składania wniosków
Zobacz inne projekty w ramach tego zaproszeniaSzczegółowe działanie
H2020-SMEINST-1-2015
System finansowania
SME-1 - SME instrument phase 1Koordynator
7670301 REHOVOT
Izrael
Organizacja określiła się jako MŚP (firma z sektora małych i średnich przedsiębiorstw) w czasie podpisania umowy o grant.